Pelcitoclax
Pelcitoclax (APG-1252) is a potent Bcl-2/Bcl-xl inhibitor with antineoplastic and pro-apoptotic effects[1].
Product Specifications
CAS Number
[1619923-36-2]
Product Name Alternative
APG-1252
UNSPSC
12352005
Target
Apoptosis; Bcl-2 Family
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pelcitoclax.html
Purity
99.70
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C(C1CCN(CC[C@@H](NC2=CC=C(S(=O)(NC3=CC=C(N4CCN(C5=CC(F)=CC(C6=C(C7=CC=C(Cl)C=C7)N(C(C)C)C(C)=C6S(=O)(C)=O)=C5)CC4)C=C3)=O)C=C2S(=O)(C(F)(F)F)=O)CSC8=CC=CC=C8)CC1)OCCCP(O)(O)=O
Molecular Formula
C57H66ClF4N6O11PS4
Molecular Weight
1281.85
References & Citations
[1]Hanjie Yi, et al. Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 2020 Jun;9 (12) :4197-4206.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
247760-AP 100 µL
ITGB2 (Integrin, beta 2 (Complement Component 3 Receptor 3 and 4 Subunit), CD18, LAD, LCAMB, LFA-1, MAC-1, MF17, MFI7) (AP) discontinued
Ask
View Details